Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Targeting SLAMF7 in myeloma

Katja Weisel • 31 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies CAR-T Dexamethasone Elotuzumab Lenalidomide Pomalidomide
ELOQUENT-2 ELOQUENT-3

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses elotuzumab, a monoclonal antibody targeting SLAMF7, in relapsed/refractory multiple myeloma. Additionally, Dr Weisel reveals that SLAMF7 is an important target for CAR T-cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Katja Weisel

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
Ocular adverse events with ADCs
1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
ADCs for the treatment of myeloma
3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
MRD: from clinical trials to clinical practice
1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Katja Weisel • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Katja Weisel • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Katja Weisel • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Katja Weisel • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals